Revance Therapeutics Stock Price Target and Analyst Ratings (NASDAQ:RVNC)

Analyst Price Target for RVNC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$32.83

▲ +30.55% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for Revance Therapeutics in the last 3 months. The average price target is $32.83, with a high forecast of $45.00 and a low forecast of $15.00. The average price target represents a 30.55% upside from the last price of $25.15.

Buy

The current consensus among 7 investment analysts is to buy stock in Revance Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/11/2019

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

12/10/2019

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/9/2020

0 strong buy ratings
8 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/7/2020

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/5/2020

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

12/4/2020

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

2/2/2021

0 strong buy ratings
6 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/4/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/1/2021	HC Wainwright	Boost Price Target	Buy	$33.00 ➝ $35.00	Low	i
2/23/2021	Mizuho	Boost Price Target	Positive ➝ Buy	$30.00 ➝ $33.00	High	i
2/23/2021	HC Wainwright	Boost Price Target	Buy	$33.00 ➝ $35.00	High	i
1/8/2021	Needham & Company LLC	Boost Price Target	Buy	$42.00 ➝ $45.00	High	i
11/10/2020	Mizuho	Lower Price Target	Buy	$32.00 ➝ $30.00	High	i Rating by Difei Yang at Mizuho
10/26/2020	Barclays	Boost Price Target	Overweight	$35.00 ➝ $38.00	Medium	i
10/15/2020	Needham & Company LLC	Boost Price Target	Buy	$36.00 ➝ $42.00	Low	i
10/15/2020	HC Wainwright	Boost Price Target	Buy	$27.00 ➝ $33.00	Low	i Rating by Douglas Tsao at HC Wainwright
9/28/2020	Barclays	Boost Price Target	Overweight	$32.00 ➝ $35.00	Low	i
8/11/2020	Mizuho	Initiated Coverage	Buy	$32.00	Low	i Rating by Difei Yang at Mizuho
7/10/2020	HC Wainwright	Reiterated Rating	Buy	$27.00	Medium	i Rating by Douglas Tsao at HC Wainwright
6/2/2020	HC Wainwright	Reiterated Rating	Buy	$24.00	Medium	i Rating by Douglas Tsao at HC Wainwright
5/20/2020	Mizuho	Reiterated Rating	Buy	$35.00	Low	i
4/16/2020	Stifel Nicolaus	Lower Price Target	Buy	$35.00 ➝ $31.00	High	i
4/15/2020	Needham & Company LLC	Reiterated Rating	Buy	$36.00	High	i
4/1/2020	Mizuho	Reiterated Rating	Buy	$39.00 ➝ $35.00	High	i
3/27/2020	William Blair	Reiterated Rating	Buy		Medium	i
3/27/2020	HC Wainwright	Reiterated Rating	Buy	$28.00 ➝ $24.00	Medium	i Rating by D. Tsao at HC Wainwright
3/22/2020	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$32.00 ➝ $15.00	Medium	i Rating by Terence Flynn at The Goldman Sachs Group, Inc.
2/26/2020	HC Wainwright	Reiterated Rating	Buy	$23.00 ➝ $28.00	Low	i Rating by Douglas Tsao at HC Wainwright
2/25/2020	Piper Sandler	Boost Price Target	Overweight	$37.00 ➝ $40.00	High	i
2/25/2020	Needham & Company LLC	Boost Price Target	Buy	$32.00 ➝ $36.00	High	i
2/18/2020	Piper Sandler	Lower Price Target	Overweight	$38.00 ➝ $37.00	Low	i
1/23/2020	Mizuho	Boost Price Target	Buy ➝ Positive	$34.00 ➝ $39.00	Low	i
12/2/2019	The Goldman Sachs Group	Initiated Coverage	Buy	$25.00	High	i
11/5/2019	Mizuho	Reiterated Rating	Buy	$34.00	High	i
10/30/2019	Wells Fargo & Company	Upgrade	Market Perform ➝ Outperform	$12.50 ➝ $20.00	High	i
10/15/2019	HC Wainwright	Set Price Target	Buy	$23.00	Medium	i Rating by Douglas Tsao at HC Wainwright
10/14/2019	Mizuho	Reiterated Rating	Buy	$34.00	High	i
8/6/2019	William Blair	Reiterated Rating	Outperform		High	i Rating by T. Lugo at William Blair
6/11/2019	Barclays	Initiated Coverage	Overweight ➝ Overweight	$28.00	Medium	i
4/24/2019	Mizuho	Reiterated Rating	Buy	$37.00	Medium	i
3/1/2019	SunTrust Banks	Lower Price Target	Positive ➝ Buy	$29.00	High	i
2/27/2019	Mizuho	Reiterated Rating	Buy		High	i
2/15/2019	Wells Fargo & Company	Initiated Coverage	Market Perform	$17.83	Low	i
2/14/2019	HC Wainwright	Initiated Coverage	Buy	$25.00	Low	i Rating by D. Tsao at HC Wainwright
1/28/2019	Stifel Nicolaus	Initiated Coverage	Buy	$50.00	High	i
1/18/2019	Mizuho	Reiterated Rating	Buy		Medium	i
11/16/2018	Guggenheim	Upgrade	Neutral ➝ Buy	$41.00	Low	i
11/1/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$50.00	High	i Rating by Louise Chen at Cantor Fitzgerald
9/17/2018	Piper Jaffray Companies	Reiterated Rating	Buy		Low	i Rating by David Amsellem at Piper Jaffray Companies
9/17/2018	JMP Securities	Downgrade	Outperform ➝ Market Perform		High	i
9/14/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$50.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
8/2/2018	Cantor Fitzgerald	Set Price Target	Buy	$50.00	High	i Rating by Louise Chen at Cantor Fitzgerald
5/29/2018	Cantor Fitzgerald	Set Price Target	Buy	$50.00	High	i Rating by Louise Chen at Cantor Fitzgerald
5/8/2018	Cantor Fitzgerald	Set Price Target	Buy	$50.00	High	i Rating by Louise Chen at Cantor Fitzgerald
4/20/2018	Guggenheim	Reiterated Rating	Hold		High	i
4/20/2018	Mizuho	Lower Price Target	Buy	$54.00 ➝ $48.00	High	i
4/2/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$50.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
3/26/2018	Needham & Company LLC	Initiated Coverage	Buy	$42.00	Low	i
3/5/2018	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy	$60.00	Medium	i Rating by Dana Flanders at The Goldman Sachs Group, Inc.
3/1/2018	Piper Jaffray Companies	Set Price Target	Buy	$48.00	High	i Rating by David Amsellem at Piper Jaffray Companies
3/1/2018	William Blair	Reiterated Rating	Outperform		Medium	i
2/28/2018	Cantor Fitzgerald	Set Price Target	Buy	$50.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
1/17/2018	Cowen	Set Price Target	Buy	$55.00	Low	i Rating by Ken Cacciatore at Cowen Inc
1/9/2018	Guggenheim	Downgrade	Buy ➝ Hold		N/A	i
1/5/2018	Mizuho	Reiterated Rating	Buy	$54.00	Low	i
1/4/2018	Guggenheim	Reiterated Rating	Buy ➝ Neutral	$42.00	High	i
1/4/2018	Cantor Fitzgerald	Set Price Target	Buy	$50.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
12/19/2017	Barclays	Set Price Target	Overweight ➝ Buy	$40.00	High	i Rating by Douglas Tsao at Barclays PLC
12/13/2017	Cantor Fitzgerald	Set Price Target	Buy	$50.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
12/8/2017	SunTrust Banks	Boost Price Target	Buy	$53.00	Medium	i
12/6/2017	Mizuho	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $54.00	Medium	i
12/5/2017	Guggenheim	Initiated Coverage	Buy ➝ Buy	$42.00	Medium	i
12/5/2017	Piper Jaffray Companies	Boost Price Target	Positive ➝ Overweight	$28.00 ➝ $51.00	High	i Rating by David Amsellem at Piper Jaffray Companies
12/5/2017	Cantor Fitzgerald	Set Price Target	Buy	$50.00	High	i Rating by Louise Chen at Cantor Fitzgerald
11/29/2017	Cantor Fitzgerald	Set Price Target	Buy	$50.00	High	i Rating by Louise Chen at Cantor Fitzgerald
11/27/2017	Barclays	Initiated Coverage	Overweight	$31.00	Medium	i Rating by Douglas Tsao at Barclays PLC
11/16/2017	Cantor Fitzgerald	Set Price Target	Buy	$50.00	N/A	i Rating by Louise Chen at Cantor Fitzgerald
11/16/2017	Mizuho	Initiated Coverage	Buy ➝ Buy	$37.00	N/A	i
10/27/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$28.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
10/24/2017	Cantor Fitzgerald	Set Price Target	Buy	$50.00	N/A	i
9/26/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$50.00	High	i
9/6/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$50.00	Low	i
8/22/2017	JMP Securities	Initiated Coverage	Mkt Outperform ➝ Outperform	$34.00	Medium	i
7/26/2017	Piper Jaffray Companies	Set Price Target	Buy	$28.00	Low	i
7/20/2017	Cantor Fitzgerald	Initiated Coverage	Overweight	$50.00	High	i
6/8/2017	Aegis	Reiterated Rating	Buy	$36.00	Medium	i Rating by Difei Yang at Aegis
5/19/2017	Aegis	Reiterated Rating	Buy	$28.00 ➝ $36.00	Low	i Rating by Difei Yang at Aegis
5/1/2017	Aegis	Reiterated Rating	Buy	$28.00	High	i Rating by Difei Yang at Aegis
2/28/2017	Aegis	Reiterated Rating	Buy	$28.00	N/A	i Rating by Difei Yang at Aegis
1/19/2017	Aegis	Reiterated Rating	Buy	$28.00	N/A	i Rating by Difei Yang at Aegis
1/8/2017	Aegis	Set Price Target	Buy	$28.00	N/A	i Rating by Difei Yang at Aegis
11/29/2016	Aegis	Initiated Coverage	Buy	$28.00	N/A	i
8/5/2016	Brean Capital	Reiterated Rating	Hold		N/A	i Rating by Difei Yang at Brean Capital
6/23/2016	Brean Capital	Reiterated Rating	Hold		N/A	i Rating by Difei Yang at Brean Capital
6/14/2016	SunTrust Banks	Lower Price Target	Buy	$46.00 ➝ $22.00	N/A	i
6/14/2016	Brean Capital	Downgrade	Buy ➝ Hold		N/A	i Rating by Difei Yang at Brean Capital
6/14/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$54.00 ➝ $35.00	N/A	i
6/14/2016	Guggenheim	Reiterated Rating	Buy	$55.00	N/A	i Rating by Louise Chen at Guggenheim
6/4/2016	Brean Capital	Reiterated Rating	Buy		N/A	i Rating by Difei Yang at Brean Capital
5/24/2016	Brean Capital	Reiterated Rating	Buy	$48.00	N/A	i Rating by Difei Yang at Brean Capital
5/10/2016	Brean Capital	Reiterated Rating	Buy		N/A	i Rating by Difei Yang at Brean Capital
4/11/2016	Guggenheim	Reiterated Rating	Buy	$55.00	N/A	i Rating by Louise Chen at Guggenheim
3/23/2016	SunTrust Banks	Initiated Coverage	Buy	$46.00	N/A	i
3/16/2016	Brean Capital	Initiated Coverage	Buy	$48.00	N/A	i
3/4/2016	Guggenheim	Reiterated Rating	Buy	$55.00	N/A	i

(Data available from 3/4/2016 forward)

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX; and collaboration and license agreement with Mylan N.V. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.

Today's Range

Now: $25.15

$24.94

$25.80

50 Day Range

MA: $27.88

$25.35

$29.97

52 Week Range

Now: $25.15

$11.78

$34.62

Volume

13,753 shs

Average Volume

450,271 shs

Market Capitalization

$1.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Revance Therapeutics?

The following Wall Street sell-side analysts have issued reports on Revance Therapeutics in the last year: Barclays PLC, HC Wainwright, Mizuho, Needham & Company LLC, Stifel Nicolaus, The Goldman Sachs Group, Inc., William Blair, and Zacks Investment Research.
View the latest analyst ratings for RVNC.

What is the current price target for Revance Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Revance Therapeutics in the last year. Their average twelve-month price target is $32.83, suggesting a possible upside of 26.0%. Needham & Company LLC has the highest price target set, predicting RVNC will reach $45.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $15.00 for Revance Therapeutics in the next year.
View the latest price targets for RVNC.

What is the current consensus analyst rating for Revance Therapeutics?

Revance Therapeutics currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RVNC will outperform the market and that investors should add to their positions of Revance Therapeutics.
View the latest ratings for RVNC.

What other companies compete with Revance Therapeutics?

Other companies that are similar to Revance Therapeutics include GW Pharmaceuticals, Evotec, Allakos, Atea Pharmaceuticals, Maravai LifeSciences, TG Therapeutics, Perrigo, Blueprint Medicines, Turning Point Therapeutics, Galapagos, Emergent BioSolutions, Biohaven Pharmaceutical, Sage Therapeutics, Eidos Therapeutics and Arena Pharmaceuticals.

How do I contact Revance Therapeutics' investor relations team?

Revance Therapeutics' physical mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company's listed phone number is 510-742-3400 and its investor relations email address is [email protected] The official website for Revance Therapeutics is www.revance.com.

NASDAQ:RVNC - Revance Therapeutics Stock Price Target and Predictions

Analyst Price Target for RVNC

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Revance Therapeutics?

What is the current price target for Revance Therapeutics?

What is the current consensus analyst rating for Revance Therapeutics?

What other companies compete with Revance Therapeutics?

How do I contact Revance Therapeutics' investor relations team?